普托马尼、贝达喹啉和利奈唑胺相关药物性肝损伤:FAERS数据库分析
本研究基于FAERS数据库2019年7月至2023年6月数据,回顾性分析BPaL方案与HRZE方案相关药物性肝损伤(DILI)的报告风险。BPaL方案相关DILI报告1242例,总体报告比值比(ROR=4.75)低于HRZE方案(ROR=7.99),但BPaL方案DILI中位发生时间更短(8天 vs 20天),且DILI相关死亡率更高(14.1% vs 10.4%)。提示BPaL方案虽总体DILI风险较低,仍需密切监测。
要点
- BPaL方案相关DILI报告1242例,总体DILI报告风险低于HRZE方案。
- BPaL方案DILI中位发生时间8天,显著短于HRZE方案的20天。
- BPaL方案DILI相关死亡率14.1%,高于HRZE方案的10.4%。
核心结论
- BPaL方案总体DILI报告风险低于HRZE方案,但仍与DILI显著相关,且DILI相关死亡风险更高,治疗期间需密切监测。
研究设计与样本
- 回顾性药物警戒分析,使用美国FDA不良事件报告系统数据库2019年7月至2023年6月数据,采用比例失衡分析计算ROR。
主要发现
- 识别BPaL相关DILI病例1242例,其中63.8%为65岁以下人群,男性占51.4%、女性占39.5%。
- HRZE方案与DILI关联的ROR=7.99(95%CI 7.74-8.25),BPaL方案ROR=4.75(95%CI 4.55-4.97)。
临床怎么用
- 使用BPaL方案治疗耐药结核病时,应关注DILI风险,尤其在治疗早期(中位8天)加强肝功能监测。
- BPaL方案相关DILI虽总体报告风险较低,但死亡风险较高,需警惕严重肝损伤并及时干预。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: The emergence of drug-resistant tuberculosis has necessitated novel treatments like the pretomanid, bedaquiline and linezolid (BPaL) regimen. This study investigated the association of drug-induced liver injury (DILI) with the BPaL regimen compared to first-line antituberculosis drugs (isoniazid, rifampin, pyrazinamide and ethambutol [HRZE]). METHODS: A retrospective pharmacovigilance analysis was conducted using data from the US Food and Drug Administration Adverse Event Reporting System database from July 2019 to June 2023. Disproportionality analysis was employed to calculate the reporting odds ratio (ROR) of DILI for each component of the BPaL regimen. Onset time and mortality rates of DILI across different regimens were also compared. RESULTS: We identified 1242 cases of BPaL-related DILI. Most cases occurred in individuals under 65 years of age (63.8%), with more male patients affected than females (51.4% vs 39.5%). The association between antituberculosis drugs and DILI was stronger for the HRZE regimen (ROR = 7.99, 95% confidence interval [CI] 7.74-8.25) than the BPaL regimen (ROR = 4.75, 95% CI 4.55-4.97). The median onset time for DILI was significantly shorter with the BPaL regimen (8 days, interquartile range [IQR] 3-28) compared to the HRZE regimen (20 days, IQR 6-48) (P < .001). Additionally, the BPaL regimen was associated with a higher risk of death due to DILI compared to the HRZE regimen (14.1% vs 10.4%, P = .003). CONCLUSIONS: Although the BPaL regimen had a lower overall risk of DILI compared to the HRZE regimen, it was significantly associated with DILI, indicating a need for careful monitoring during treatment.
引用
- He Q, Li Y, Liu S, et al. Drug-induced liver injury associated with pretomanid, bedaquiline, and linezolid: Insights from FAERS database analysis. Br J Clin Pharmacol. 2024. PMID: 39419512. doi:10.1111/bcp.16318
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。